Senseonics Holdings Inc (SENS)
NASDAQ:SENS
SENS Stock Chart & Stats
$6.72
-$0.03(-6.68%)
At close: 4:00 PM EST
$6.72
-$0.03(-6.68%)
Day’s Range― - ―
52-Week Range$5.25 - $15.76
Previous CloseN/A
Volume3.00M
Average Volume (3M)459.87K
Market Cap
$279.03M
Enterprise Value$281.52M
Total Cash (Recent Filing)$94.03M
Total Debt (Recent Filing)$41.37M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 07, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding41,770,466
10 Day Avg. Volume262,462
30 Day Avg. Volume459,874
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue7.63
Enterprise Value/Gross Profit16.97
Enterprise Value/Ebitda-5.27
Forecast
1Y Price Target
$18.92Price Target Upside181.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$60.07M
Bulls Say, Bears Say
Bulls Say
Product Integration And AdoptionFull market release of the product integrated with a popular automated insulin delivery system is expected to increase adoption among Type 1 patients and expand the addressable market.
Profitability And MarginsMaterial improvement in gross margins following the Ascensia transition supports a more sustainable path to margin expansion and improved profitability.
Regulatory ApprovalCE mark approval for Eversense 365 as the first year‑long continuous glucose monitoring system in the EU enables regulatory market access and supports European commercialization.
Bears Say
Clinician Adoption ConcernsSome clinicians reported concerns about consistent sensor placement and the sensor's visibility, which limited their willingness to prescribe the device.
Marketing Spend And Operating ExpensesPlanned continued heavy direct‑to‑consumer marketing and elevated operating expenses could pressure profitability and delay a clear path to positive earnings.
Valuation And Analyst SentimentShares appear fairly valued on an enterprise‑value‑to‑sales basis, supporting the analyst's Neutral rating and limiting upside from revaluation.
Senseonics Holdings News
SENS FAQ
What was Senseonics Holdings Inc’s price range in the past 12 months?
Senseonics Holdings Inc lowest stock price was $5.25 and its highest was $15.76 in the past 12 months.
What is Senseonics Holdings Inc’s market cap?
Senseonics Holdings Inc’s market cap is $279.03M.
When is Senseonics Holdings Inc’s upcoming earnings report date?
Senseonics Holdings Inc’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were Senseonics Holdings Inc’s earnings last quarter?
Senseonics Holdings Inc released its earnings results on Mar 02, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.435 by -$0.025.
Is Senseonics Holdings Inc overvalued?
According to Wall Street analysts Senseonics Holdings Inc’s price is currently Undervalued.
Does Senseonics Holdings Inc pay dividends?
Senseonics Holdings Inc does not currently pay dividends.
What is Senseonics Holdings Inc’s EPS estimate?
Senseonics Holdings Inc’s EPS estimate is -0.69.
How many shares outstanding does Senseonics Holdings Inc have?
Senseonics Holdings Inc has 41,770,466 shares outstanding.
What happened to Senseonics Holdings Inc’s price movement after its last earnings report?
Senseonics Holdings Inc reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.435. Following the earnings report the stock price went down -18.067%.
Which hedge fund is a major shareholder of Senseonics Holdings Inc?
Currently, no hedge funds are holding shares in SENS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Senseonics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.92 (181.55% Upside)
$18.92 (181.55% Upside)
Blogger Sentiment
Bullish
SENS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 608.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.50%
12-Months-Change
Fundamentals
Return on Equity
-104.17%
Trailing 12-Months
Asset Growth
25.72%
Trailing 12-Months
Company Description
Senseonics Holdings Inc
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
SENS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates strong commercial momentum and significant operational progress: robust revenue growth (full-year +~57% to $35.3M), doubling of the U.S. patient base, major margin expansion to >50%, CE marking and a strategic pump integration, and an aggressive 2026 revenue guide (+65% to +76%). These positives are tempered by deliberate, large near-term investments—notably a planned $150M–$160M operating cost base in 2026, $110M–$120M projected cash burn, higher SG&A and transitional commission costs—which will keep the company unprofitable near term and create execution and timing risks (especially in Europe and due to seasonality). Overall, the call framed 2025 as a transformation year with an operational playbook in place to scale in 2026; upside exists if patient retention, DTC efficiency and additional pump partnerships accelerate adoption, while the main risks are the heavy short-term cash and expense commitments required to capture that growth.View all SENS earnings summariesSENS Stock 12 Month Forecast
Average Price Target
$18.92
▲(181.55% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---